Weak Value Amplification Based Optical Sensor for High Throughput Real-Time Immunoassay of SARS-CoV-2 Spike Protein.

Weak Value Amplification Based Optical Sensor for High Throughput Real-Time Immunoassay of SARS-CoV-2 Spike Protein.

Publication date: Jul 08, 2024

The demand for accurate and efficient immunoassays calls for the development of precise, high-throughput analysis methods. This paper introduces a novel approach utilizing a weak measurement interface sensor for immunoassays, offering a solution for high throughput analysis. Weak measurement is a precise quantum measurement method that amplifies the weak value of a system in the weak interaction through appropriate pre- and post-selection states. To facilitate the simultaneous analysis of multiple samples, we have developed a chip with six flow channels capable of conducting six immunoassays concurrently. We can perform real-time immunoassay to determine the binding characteristics of spike protein and antibody through real-time analysis of the flow channel images and calculating the relative intensity. The proposed method boasts a simple structure, eliminating the need for intricate nano processes. The spike protein concentration and relative intensity curve were fitted using the Log-Log fitting regression equation, and R was 0. 91. Utilizing a pre-transformation approach to account for slight variations in detection sensitivity across different flow channels, the present method achieves an impressive limit of detection(LOD) of 0. 85 ng/mL for the SARS-CoV-2 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with a system standard deviation of 5. 61. Furthermore, this method has been successfully verified for monitoring molecular-specific binding processes and differentiating binding capacities.

Open Access PDF

Concepts Keywords
Basel Biosensing Techniques
Biosensors COVID-19
Conducting high throughput immunoassay
Coronavirus High-Throughput Screening Assays
Weak Humans
Immunoassay
Limit of Detection
optical biosensor
SARS-CoV-2
SARS-CoV-2 spike protein
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
weak measurement

Semantics

Type Source Name
disease VO time
disease VO efficient
disease VO Severe acute respiratory syndrome coronavirus 2
drug DRUGBANK Guanosine
drug DRUGBANK Cysteamine
disease MESH COVID 19 pandemic
disease MESH death
disease IDO symptom
drug DRUGBANK Coenzyme M
disease VO organization
disease MESH emergency
drug DRUGBANK Angiotensin II
disease IDO host
drug DRUGBANK Methylergometrine
disease MESH infection
disease IDO infectivity
disease VO Tir
disease IDO process
drug DRUGBANK Phosphate ion
disease VO company
drug DRUGBANK Tromethamine
disease MESH SD1
disease VO USA
drug DRUGBANK Tricyclazole
disease VO syringe
drug DRUGBANK Sodium Chloride
disease IDO assay
drug DRUGBANK Dopamine
disease IDO biological process
drug DRUGBANK Flunarizine
drug DRUGBANK Gold
disease VO effective
disease VO protocol
disease MESH pneumonia
disease IDO contact tracing
disease VO population
drug DRUGBANK Kale
disease VO vaccine
drug DRUGBANK Troleandomycin
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease VO vaccination
disease VO Glycoprotein

Original Article

(Visited 1 times, 1 visits today)